Axial: Connecting the Microbiome and Human Health to Improve Lives
As the scientific leader in the biological role of the microbiome and its impact on human health, Axial Therapeutics is uniquely positioned to advance a fundamentally different therapeutic approach for the treatment of many diseases and disorders. With an initial focus in neurological disease and disorders and rooted in a decade of researched focused on the gut-brain axis, we stand apart through our focus on the microbiome, harnessing our expertise to identify new drug targets in the gut and develop novel small molecule therapeutics that have significant potential for improving symptoms and treating underlying disease.
NEW DRUG TARGETS. BOLD MICROBIOME-INSPIRED THERAPEUTICS®
Our focus on the microbiome-gut interface is a transformational shift from traditional approaches to drug discovery. By identifying bacteria and their products in the gut that are linked to the pathology, progression, and symptoms of diseases and disorders, we are able to validate druggable therapeutic targets in the gut microbiome. Based on these new classes of targets, we focus on developing small molecule therapies with defined mechanisms of action that mitigate the impact of bacteria and their products. Our localized, gut-targeted small molecule approach represents an evolution in the microbiome field where development of Microbiome-Inspired Therapeutics® for a wide range of disease conditions is now possible.
New Drug Targets. Inventive Therapies. Axial is blazing a new trail in the treatment of neurological diseases and disorders.
Novel Treatments for Patients with Autism and Parkinson’s Disease
Axial’s world-class expertise in microbiome gut-brain biology combines with the robust capabilities of our discovery platform to provide the foundation for our current and future pipeline of small molecule drugs for neurodegenerative diseases and neurodevelopmental disorders. Our lead programs are focused on the treatment of irritability in autism, and the slowing of disease progression in Parkinson’s disease. We are also leveraging our Microbial-Inspired Therapeutics® discovery platform to identify and validate druggable gut-restricted targets for liver disease and oncology indications.
Unique Expertise in Gut-Brain Biology, Small Molecule Development
Led by a world-class management team that has extensive experience advancing small molecule therapies from discovery to commercialization, Axial is an industry leader in harnessing the gut-brain axis to treat disease and improve patients’ lives.
